Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy Comparison (Sitagliptin vs Dapagliflozin vs Lobeglitazone) in T2DM
NCT02338921Phase 4Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jan 2015
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin Arm, Dapagliflozin Arm and Lobeglitazone Arm (3 arms). Primary endpoint: Glycemic target goal achievement rate at 24 months. Started Jan 2015; status: completed.
02
Drugs
sitagliptindapagliflozinlobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02338921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338921.